Elizabeth Anne Mason

Elizabeth Anne Mason

Auto-generated profile, based on publicly available information

Elizabeth Anne Mason

Peter MacCallum Cancer Centre

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2015 in Development
Verified
Journal Article
Closed access
PDF file
KDKathryn C. Davidson
Kathryn C. Davidson
EMElizabeth A. Mason
Elizabeth A. Mason
MPMartin F. Pera
Martin F. Pera
In the mouse, naïve pluripotent stem cells (PSCs) are thought to represent the cell culture equivalent of the late epiblast in the pre-implantation embryo, with which they share a unique defining set of features. Recent studies have focused on the identification and propagation of a similar cell state in human. Although the capture of an exact human equivalent of the mouse naïve PSC remains an elusive goal, comparative studies spurred on by this quest are lighting the path to a deeper understanding of pluripotent state regulation in early mammalian development.

1 June 2014 in Stem Cell Reports
Verified
Journal Article
Open access
SHShelley R. Hough
Shelley R. Hough
MTMatthew Thornton
Matthew Thornton
EMElizabeth Mason
Elizabeth Mason
JMJessica C. Mar
Jessica C. Mar
CWChristine A. Wells
Christine A. Wells
MPMartin F. Pera
Martin F. Pera
Pluripotent stem cells display significant heterogeneity in gene expression, but whether this diversity is an inherent feature of the pluripotent state remains unknown. Single-cell gene expression analysis in cell subsets defined by surface antigen expression revealed that human embryonic stem cell cultures exist as a continuum of cell states, even under defined conditions that drive self-renewal. The majority of the population expressed canonical pluripotency transcription factors and could differentiate into derivatives of all three germ layers. A minority subpopulation of cells displayed high self-renewal capacity, consistently high transcripts for all pluripotency-related genes studied, and no lineage priming. This subpopulation was characterized by its expression of a particular set of intercellular signaling molecules whose genes shared common regulatory features. Our data support a model of an inherently metastable self-renewing population that gives rise to a continuum of intermediate pluripotent states, which ultimately become primed for lineage specification.

1 March 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
DFDustin J. Flanagan
Dustin J. Flanagan
NBNick Barker
Nick Barker
NCNatasha S. Di Costanzo
Natasha S. Di Costanzo
EMElizabeth Anne Mason
Elizabeth Anne Mason
AGAustin Gurney
Austin Gurney
Elizabeth VincanElizabeth Vincan
Elizabeth Vincan
A subset of patients with gastric cancer have mutations in genes that participate in or regulate Wnt signaling at the level of ligand (Wnt) receptor (Fzd) binding. Moreover, increased Fzd expression is associated with poor clinical outcome. Despite these findings, there are no in vivo studies investigating the potential of targeting Wnt receptors for treating gastric cancer, and the specific Wnt receptor transmitting oncogenic Wnt signaling in gastric cancer is unknown. Here, we use inhibitors of Wnt/Fzd (OMP-18R5/vantictumab) and conditional gene deletion to test the therapeutic potential of targeting Wnt signaling in preclinical models of intestinal-type gastric cancer and ex vivo organoid cultures. Pharmacologic targeting of Fzd inhibited the growth of gastric adenomas in vivo. We identified Fzd7 to be the predominant Wnt receptor responsible for transmitting Wnt signaling in human gastric cancer cells and mouse models of gastric cancer, whereby Fzd7-deficient cells were retained in gastric adenomas but were unable to respond to Wnt signals and consequently failed to proliferate. Genetic deletion of Fzd7 or treatment with vantictumab was sufficient to inhibit the growth of gastric adenomas with or without mutations to Apc. Vantictumab is currently in phase Ib clinical trials for advanced pancreatic, lung, and breast cancer. Our data extend the scope of patients that may benefit from this therapeutic approach as we demonstrate that this drug will be effective in treating patients with gastric cancer regardless of APC mutation status. Significance: The Wnt receptor Fzd7 plays an essential role in gastric tumorigenesis irrespective of Apc mutation status, therefore targeting Wnt/Fzd7 may be of therapeutic benefit to patients with gastric cancer.

8 November 2021 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
KKKatarzyna Koltowska
Katarzyna Koltowska
KOKazuhide Shaun Okuda
Kazuhide Shaun Okuda
MGMarleen Gloger
Marleen Gloger
MRMaria Rondon-Galeano
Maria Rondon-Galeano
EMElizabeth Mason
Elizabeth Mason
BHBenjamin M. Hogan
Benjamin M. Hogan

24 March 2016 in PeerJ
Verified
Journal Article
Open access
PDF file
FRFlorian Rohart
Florian Rohart
EMElizabeth A. Mason
Elizabeth A. Mason
NMNicholas Matigian
Nicholas Matigian
RMRowland Mosbergen
Rowland Mosbergen
OKOthmar Korn
Othmar Korn
CWChristine A. Wells
Christine A. Wells
Mesenchymal stromal cells (MSC) are widely used for the study of mesenchymal tissue repair, and increasingly adopted for cell therapy, despite the lack of consensus on the identity of these cells. In part this is due to the lack of specificity of MSC markers. Distinguishing MSC from other stromal cells such as fibroblasts is particularly difficult using standard analysis of surface proteins, and there is an urgent need for improved classification approaches. Transcriptome profiling is commonly used to describe and compare different cell types; however, efforts to identify specific markers of rare cellular subsets may be confounded by the small sample sizes of most studies. Consequently, it is difficult to derive reproducible, and therefore useful markers. We addressed the question of MSC classification with a large integrative analysis of many public MSC datasets. We derived a sparse classifier (The Rohart MSC test) that accurately distinguished MSC from non-MSC samples with >97% accuracy on an internal training set of 635 samples from 41 studies derived on 10 different microarray platforms. The classifier was validated on an external test set of 1,291 samples from 65 studies derived on 15 different platforms, with >95% accuracy. The genes that contribute to the MSC classifier formed a protein-interaction network that included known MSC markers. Further evidence of the relevance of this new MSC panel came from the high number of Mendelian disorders associated with mutations in more than 65% of the network. These result in mesenchymal defects, particularly impacting on skeletal growth and function. The Rohart MSC test is a simplein silicotest that accurately discriminates MSC from fibroblasts, other adult stem/progenitor cell types or differentiated stromal cells. It has been implemented in thewww.stemformatics.orgresource, to assist researchers wishing to benchmark their own MSC datasets or data from the public domain. The code is available from the CRAN repository and all data used to generate the MSC test is available to download via the Gene Expression Omnibus or the Stemformatics resource.

15 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KLKevin X. Lau
Kevin X. Lau
EMElizabeth A. Mason
Elizabeth A. Mason
JKJoshua Kie
Joshua Kie
DAVID DE SOUZADAVID DE SOUZA
DAVID DE SOUZA
JKJoachim Kloehn
Joachim Kloehn
MPMartin F. Pera
Martin F. Pera
Archetypal human pluripotent stem cells (hPSC) are widely considered to be equivalent in developmental status to mouse epiblast stem cells, which correspond to pluripotent cells at a late post-implantation stage of embryogenesis. Heterogeneity within hPSC cultures complicates this interspecies comparison. Here we show that a subpopulation of archetypal hPSC enriched for high self-renewal capacity (ESR) has distinct properties relative to the bulk of the population, including a cell cycle with a very low G1 fraction and a metabolomic profile that reflects a combination of oxidative phosphorylation and glycolysis. ESR cells are pluripotent and capable of differentiation into primordial germ cell-like cells. Global DNA methylation levels in the ESR subpopulation are lower than those in mouse epiblast stem cells. Chromatin accessibility analysis revealed a unique set of open chromatin sites in ESR cells. RNA-seq at the subpopulation and single cell levels shows that, unlike mouse epiblast stem cells, the ESR subset of hPSC displays no lineage priming, and that it can be clearly distinguished from gastrulating and extraembryonic cell populations in the primate embryo. ESR hPSC correspond to an earlier stage of post-implantation development than mouse epiblast stem cells.